Showing 1231-1240 of 5000 results for "".
Sensus Healthcare: What's New
https://practicaldermatology.com/topics/skin-cancer-photoprotection/sensus-healthcare-whats-new/19946/Adding to its flagship SRT-100 device for superficial radiation therapy, Sensus has launched the Sculptura® Radiotherapy Oncology System and is poised to bring new aesthetic devices to market. Sensus CEO Joe Sardano says that as it grows, the company remains focused on relationships with its clientsAlmost There: Toward Systemic Therapy for AD in Children
https://practicaldermatology.com/topics/atopic-dermatitis/almost-there-toward-systemic-therapy-for-ad-in-children/19934/With the approval of the first biologic for management of atopic dermatitis, a new era is underway, says Amy Paller, MD. She addresses the role of dupilumab in practice and provides a look ahead at other agents in the pipeline for adolescent and pediatric patients.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.What's the last show you binge-watched?
https://practicaldermatology.com/topics/general-topics/whats-the-last-show-you-binge-watched/19875/Nazanin Saedi, MD tells us which show made her laugh and how she can't wait for the next season!PsO Treatment Guidelines: The Role of Systemic Medications
https://practicaldermatology.com/topics/psoriasis/pso-treatment-guidelines-the-role-of-systemic-medications/19649/Biologics and new JAK inhibitors play an important role in managing psoriasis. Neal Bhatia, MD offers his thoughts on when and why these treatments should be considered.What's the Best Approach to Lichen Planus?
https://practicaldermatology.com/topics/general-topics/what-s-the-best-approach-to-lichen-planus/18286/Lichen planus doesn't garner much attention in therapeutic discussions, perhaps because it is so challenging to treat. Kevin Wang, MD, PhD talks to host Adam Friedman, MD about the challenges of managing the disease and his approach to patient care.Combatting Disparities in Dermatology
https://practicaldermatology.com/topics/general-topics/combatting-disparities-in-dermatology/18338/Research shows disparities in dermatology exisit. Junko Takeshita, MD, PhD, MSCE discusses some examples, such as racial disaparities in which patients recieve biolgics to treat severe psoriasis. She also shares tips on how to determine what implicit biases you may have to race, gender, weight, etc.Avoid the Three Most Common Asset Protection Mistakes
https://practicaldermatology.com/topics/practice-management/avoid-the-three-most-common-asset-protection-mistakes/18368/OJM Group principal David Mandell, JD, MBA discusses the importance of protecting personal and business assets from lawsuits, and outlines strategies to avoid the three asset protection mistakes made by most doctors. Click here to request or download a free copy of Wealth Protection Planning for DeUpdate on Pediatric Vulvar Lichen Sclerosis
https://practicaldermatology.com/topics/general-topics/update-on-pediatric-vulvar-lichen-sclerosis/18733/Pediatric vulvar lichen sclerosis may be under-recognized. Pediatric dermatologist Kalyan Marathe, MD talks to host Adam Friedman, MD about the importance of identifying and treating the condition, providing relief to patients and potentially avoiding unnecessary testing.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder o